Statistical designs for early stage cancer clinical trials, which include continual reassessment method for phase I and I-II studies, early stopping of phase II studies, randomized phase II and multi-stage phase II studies, are shortly reviewed. These recent proposals should be examined further as regards to their statistical characteristics as well as their ethical implication.